Reuters logo
BRIEF-Cellectar Biosciences reports partial response in a relapsed or refractory multiple myeloma patient treated with CLR 131
September 27, 2017 / 12:54 PM / 2 months ago

BRIEF-Cellectar Biosciences reports partial response in a relapsed or refractory multiple myeloma patient treated with CLR 131

Sept 27 (Reuters) - Cellectar Biosciences Inc

* Cellectar Biosciences reports cohort four data and partial response in relapsed or refractory multiple myeloma patient treated with CLR 131

* Cellectar Biosciences Inc - ‍trial’s data monitoring committee determined that fourth cohort dose of 31.25 MCI/M2 was safe and tolerated​

* Cellectar Biosciences Inc - ‍company intends to advance compound into a fifth cohort using a multi-dose regimen​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below